Recent studies are focusing on identifying predictive biomarkers, such as PD-L1 expression, tumor mutational burden (TMB) and Tumor-infiltrating lymphocytes (TILs), and on optimizing therapeutic combinations to further improve the outcomes and to reduce adverse drug reactions [33,34,35]. This evidence concerns the gene CD274 and neoplasm.